Assembly Biosciences (ASMB) Competitors $14.95 +0.65 (+4.55%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ASMB vs. NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Assembly Biosciences vs. Nektar Therapeutics Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Assembly Biosciences (NASDAQ:ASMB) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment. Does the media prefer ASMB or NKTR? In the previous week, Nektar Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 1 mentions for Nektar Therapeutics and 0 mentions for Assembly Biosciences. Nektar Therapeutics' average media sentiment score of 0.00 beat Assembly Biosciences' score of -0.55 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Assembly Biosciences Negative Nektar Therapeutics Neutral Do insiders & institutionals have more ownership in ASMB or NKTR? 19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate ASMB or NKTR? Assembly Biosciences currently has a consensus price target of $35.00, indicating a potential upside of 134.11%. Nektar Therapeutics has a consensus price target of $4.08, indicating a potential upside of 344.81%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Nektar Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is ASMB or NKTR more profitable? Assembly Biosciences has a net margin of -144.05% compared to Nektar Therapeutics' net margin of -180.70%. Assembly Biosciences' return on equity of -121.46% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Assembly Biosciences-144.05% -121.46% -34.56% Nektar Therapeutics -180.70%-173.28%-46.31% Does the MarketBeat Community believe in ASMB or NKTR? Nektar Therapeutics received 391 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.84% of users gave Nektar Therapeutics an outperform vote while only 58.84% of users gave Assembly Biosciences an outperform vote. CompanyUnderperformOutperformAssembly BiosciencesOutperform Votes24358.84% Underperform Votes17041.16% Nektar TherapeuticsOutperform Votes63470.84% Underperform Votes26129.16% Which has more volatility and risk, ASMB or NKTR? Assembly Biosciences has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Which has stronger valuation & earnings, ASMB or NKTR? Assembly Biosciences has higher earnings, but lower revenue than Nektar Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAssembly Biosciences$7.16M13.28-$61.23MN/AN/ANektar Therapeutics$90.12M1.88-$276.06M-$0.84-1.09 SummaryNektar Therapeutics beats Assembly Biosciences on 11 of the 17 factors compared between the two stocks. Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.08M$6.55B$5.40B$9.24BDividend YieldN/A2.96%5.37%3.99%P/E RatioN/A9.9389.1417.52Price / Sales13.28335.641,226.4979.25Price / CashN/A64.1243.6036.96Price / Book1.995.105.014.72Net Income-$61.23M$154.90M$117.89M$224.61M7 Day Performance3.10%1.58%1.91%1.54%1 Month Performance-1.71%1.75%3.89%5.12%1 Year Performance46.53%4.64%26.59%21.25% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences4.0944 of 5 stars$14.95+4.5%$35.00+134.1%+38.7%$95.08M$7.16M0.00100NKTRNektar Therapeutics4.1027 of 5 stars$0.96-6.7%$4.08+324.8%+69.0%$177.32M$93.14M-1.14220CPIXCumberland Pharmaceuticals0.3218 of 5 stars$2.33flatN/A+20.3%$32.72M$36.79M-3.0380Analyst ForecastNews CoverageLLYEli Lilly and Company4.9971 of 5 stars$797.17-0.3%$1,002.22+25.7%+18.0%$756.77B$40.86B86.1839,000Analyst RevisionPositive NewsJNJJohnson & Johnson4.9885 of 5 stars$144.50+1.7%$174.71+20.9%-8.4%$347.90B$87.70B20.91131,900Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap DownABBVAbbVie4.9964 of 5 stars$176.94+1.0%$205.50+16.1%+4.6%$312.68B$55.53B61.4450,000Analyst RevisionNews CoveragePositive NewsMRKMerck & Co., Inc.4.9993 of 5 stars$100.94+1.7%$123.67+22.5%-19.1%$255.34B$63.17B21.1669,000Analyst ForecastAnalyst RevisionNews CoveragePositive NewsPFEPfizer4.9935 of 5 stars$26.79+0.3%$32.00+19.4%-5.8%$151.82B$59.38B36.2088,000Positive NewsBMYBristol-Myers Squibb4.9091 of 5 stars$55.35-0.9%$56.27+1.7%+13.8%$112.26B$47.44B-15.4234,100Analyst RevisionPositive NewsZTSZoetis4.8637 of 5 stars$166.31+1.8%$211.89+27.4%-11.1%$75.03B$9.15B31.2614,100Positive NewsRPRXRoyalty Pharma4.8564 of 5 stars$29.99+1.7%$41.67+38.9%+4.2%$17.67B$2.27B15.5480Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Nektar Therapeutics Alternatives Cumberland Pharmaceuticals Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ASMB) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredThe Stock I’m Calling My #1 of the DecadeThe stock I reveal right here is my #1 stock of the decade. In fact, it might be my favorite stock ever. ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
